Table 2.
Risk of bias summary of controlled trials of quetiapine in major depressive disorder
| Study |
Issues of bias |
|||||||
|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | |
| Cutler AJ [2009] |
N |
N |
N |
N |
N |
N |
N |
N |
| Weisler R [2009] |
N |
N |
N |
N |
N |
N |
N |
N |
| Bortnick B [2011] | N/A | N/A | N | N | N | N | N | N |
1=Adequate sequence generation; 2 = Allocation concealment; 3=Blinding (Subjective outcome); 4 = Dropout data addressed; 5 = Free of selective reporting; 6 = Free of other bias; 7 = Baseline similarity; 8 = Intention-to-treat analysis or modified intention-to-treat analysis; N/A = not available; N = No risk of bias.